Cipla News and Updates

Name: Latest research reports of Cipla Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 3
Author: BOB Capital Markets Ltd.

Keep track of all breaking news on Cipla from all sources in a single place.

Cipla Ltd.

08 Mar 2026

1329.50

-0.30%

Cipla recalls over 400 cartons of cancer drug in US: USFDA

Business Line

The company is recalling the affected lot (271 and 164 cartons) due to "failed tablet/capsule specifications", it stated

Cipla Ltd. has an average target of 1627.00 from 9 brokers.

Cipla's US unit recalls 400+ cartons of generic anti-cancer drug: USFDA

Business Standard | 08 Mar 2026

Cipla Ltd.

02 Mar 2026

1329.50

-0.30%

Cipla, Kemwell form biologics JV to tap fast-growing biosimilars market

Business Standard

Cipla will hold 60% in the new JV with Kemwell Biopharma, aiming to develop, manufacture and commercialise biologics and biosimilars for global markets amid rising demand

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

27 Jan 2026

1329.50

-0.30%

Cipla shares decline post Q3; brokerages slash targets on US headwinds

Business Standard

In Q3, Cipla's net profit dropped 57 per cent year-on-year (Y-o-Y) to 675 crore, as compared to 1,570.51 crore a year ago

Cipla Ltd. has an average target of 1627.00 from 9 brokers.

Cipla Ltd.

25 Jan 2026

1329.50

-0.30%

Cipla (HOLD): A clear HOLD as valuation reflects pessimism

Hold: Cipla Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Sales/EBITDA /PAT reported -5.5%/-27.9%/-45% below our estimates. Ex of one-time cost, PAT reported 23% below our estimates

Cipla Ltd. has an average target of 1627.00 from 9 brokers.

Cipla Ltd.

24 Jan 2026

1329.50

-0.30%

EBITDA/earnings decline YoY after 13 quarters

Neutral: Cipla Ltd.

Target

Motilal Oswal

CIPLA delivered an in-line revenue. However, it posted lower-than-expected EBITDA/PAT (21%/22% miss) for the quarter. After almost 13 quarters, CIPLA exhibited a YoY decline in EBITDA in 3QFY26.

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

23 Jan 2026

1329.50

-0.30%

Cipla Q3 results: Net profit slumps 57% to 675 crore on US supply issues

Business Standard

Bets on respiratory product launches and peptides for growth

Cipla Ltd. has an average target of 1627.00 from 9 brokers.

Cipla Q3 net profit dips 57 per cent due to Lanreotide production halt

Business Line | 23 Jan 2026 1 more

Cipla Ltd.

23 Jan 2026

1329.50

-0.30%

Cipla Ltd. Results Earnings Call for Q3FY26

Conference Call with Cipla Ltd. Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.

audio

Cipla Ltd.

23 Jan 2026

1329.50

-0.30%

to see Rapid results content

Cipla Ltd.

16 Jan 2026

1329.50

-0.30%

Lanreotide supply disruption raises concerns over Cipla's earnings

Business Standard

Cipla said supplies of its key US drug Lanreotide will remain constrained after its manufacturing partner paused production following USFDA observations